NASDAQ:CTMX
CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc.'s revenue fell 44.8% in fiscal 2025 to $76.2M while operating margin fell to −29.3%. Free cash flow was −$75.8M, −99.5% of revenue, and the diluted share count rose 62.8%.Summary generated from CytomX Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 16, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$76.2M
Revenue growth−44.8%
Revenue, 5-yr CAGR+2.2%
Gross marginn/a
Operating margin−29.3%
Net margin−22.8%
ROICn/a
Return on equity−35.2%
Debt / equityn/a
Free cash flow−$75.8M
FCF margin−99.5%
Share count change+62.8%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 37 | 53 | 101 | 138 | 76 |
| Operating income | −116 | −101 | −6 | 25 | −22 |
| Net income | −116 | −99 | −1 | 32 | −17 |
| Free cash flow | −121 | −113 | −57 | −87 | −76 |
Recent filings
- 8-KResults of operations and financial condition
Aug 6, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 4Insider transaction report
Aug 5, 2026 - 4Insider transaction report
Jul 30, 2026 - 8-KDirector or officer change
Jul 27, 2026 - 8-KDirector or officer change
Jun 22, 2026 - 8-KEntry into a material agreement
Jun 3, 2026 - 8-KResults of operations and financial condition
May 7, 2026